Types of Research
- (-) Remove Risk, Preferences, & Decision-Making filter Risk, Preferences, & Decision-Making
- (-) Remove Market & Value Chain Analysis filter Market & Value Chain Analysis
- (-) Remove Research & Development filter Research & Development
While literature on achieving Inclusive Agricultural Transformation (IAT) through input market policies is relatively robust, literature on the effect of output market policies on IAT is rarer. We conduct a selective literature review of output market policies in low- and middle-income countries to assess their influence on IAT and find that outcomes are mixed across all policy areas. We also review indicators used to measure successful IAT, typologies of market institutions involved in IAT, and agricultural policies and maize yield trends in East Africa. This report details our findings on these connected, yet somewhat disparate elements of IAT to shed more light on a topic that has not been the primary focus of the literature thus far.
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
A large and growing body of scholarship now suggests that many household outcomes, including children’s education and nutrition, are associated with a wife’s bargaining power and control over household decision-making. In turn, bargaining power in a household is theorized to be driven by a wife’s financial and human capital assets – in particular the degree to which these assets contribute to household productivity and/or to the wife’s exit options. This paper draws on the detailed Farmer First dataset in Tanzania and Mali to examine husband and wife reports of a wife’s share of decision-making authority in polygynous households, where multiple wives jointly contribute to household productivity, and where exit options for any single wife may be less credible. We find that both husbands and wives assign less authority to the wife in polygynous households relative to monogamous households. We also find that a wife’s assets are not as strongly associated with decision-making authority in polygynous versus monogamous contexts. Finally, we find that responses to questions on spousal authority vary significantly by spouse in both polygynous and monogamous households, suggesting interventions based on the response of a single spouse may incorrectly inform policies and programs.
According to AGRA's 2017 Africa Agriculture Status Report, smallholder farmers make up to about 70% of the population in Africa. The report finds that 500 million smallholder farms around the world provide livelihoods for more than 2 billion people and produce about 80% of the food in sub-Saharan Africa and Asia. Many development interventions and policies therefore target smallholder farm households with the goals of increasing their productivity and promoting agricultural transformation. Of particular interest for agricultural transformation is the degree to which smallholder farm households are commercializating their agricultural outputs, and diversifying their income sources away from agriculture. In this project, EPAR uses data from the World Bank's Living Standards Measurement Study - Integrated Surveys on Agriculture (LSMS-ISA) to analyze and compare characteristics of smallholder farm households at different levels of crop commercialization and reliance on farm income, and to evaluate implications of using different criteria for defining "smallholder" households for conclusions on trends in agricultural transformation for those households.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
By examining how farmers respond to changes in crop yield, we provide evidence on how farmers are likely to respond to a yield-enhancing intervention that targets a single staple crop such as maize. Two alternate hypotheses we examine are: as yields increase, do farmers maintain output levels but change the output mix to switch into other crops or activities, or do they hold cultivated area constant to increase their total production quantity and therefore their own consumption or marketing of the crop? This exploratory data analysis using three waves of panel data from Tanzania is part of a long-term project examining the pathways between staple crop yield (a proxy for agricultural productivity) and poverty reduction in Sub-Saharan Africa.
This research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. We summarize the public good characteristics of R&D for agriculture in general and for commodity and subsistence crops in particular, as well as R&D for health in general and for neglected diseases in particular, with a focus on Sub-Saharan Africa and South Asia. Finally, we present rationales for which funders are predicted to fund which R&D types based on these funder and R&D characteristics. We then compile available statistics on funding for agricultural and health R&D from private, public and philanthropic sources, and compare trends in funding from these sources against expectations. We find private agricultural R&D spending focuses on commodity crops (as expected). However contrary to expectations we find public and philanthropic spending also goes largely towards these same crops rather than staples not targeted by private funds. For health R&D private funders similarly concentrate on diseases with higher potential financial returns. However unlike in agricultural R&D, in health R&D we observe some specialization across funders – especially for neglected diseases R&D - consistent with funders’ expected relative advantages.
A growing body of evidence suggests that empowering women may lead to economic benefits (The World Bank, 2011; Duflo, 2012; Kabeer & Natali, 2013). Little work, however, focuses specifically on the potential impacts of women’s empowerment in agricultural settings. Through a comprehensive review of literature this report considers how prioritizing women’s empowerment in agriculture might lead to economic benefits. With an intentionally narrow focus on economic empowerment, we draw on the Women’s Empowerment in Agriculture Index (WEAI)’s indicators of women’s empowerment in agriculture to consider the potential economic rewards to increasing women’s control over agricultural productive resources (including their own time and labor), over agricultural production decisions, and over agricultural income. While we recognize that there may be quantifiable benefits of improving women’s empowerment in and of itself, we focus on potential longer-term economic benefits of improvements in these empowerment measures.